New hope for easing debilitating pain in rare genetic diseases
NCT ID NCT03153319
Summary
This study is testing whether a medication called adalimumab can help reduce joint pain and improve movement in children and adults with mucopolysaccharidosis (MPS) types I, II, or VI. These are rare genetic disorders that cause severe joint stiffness and pain. For the first 16 weeks, some participants receive the drug while others receive a placebo, followed by a longer period where everyone can receive the treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUCOPOLYSACCHARIDOSIS II are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Lundquist Institute at Harbor-UCLA Medical Center
Torrance, California, 90502, United States
Conditions
Explore the condition pages connected to this study.